Successful Treatment of an Adolescent Male With Severe Refractory Evans Syndrome Using Bortezomib-based Therapy
We present a 15-year-old boy with Evans syndrome and common variable immunodeficiency who experienced a severe, refractory flare 16 months postsplenectomy. After failing to respond to multiple other agents, he achieved a durable response to a bortezomib-based regimen. Bortezomib may be a reasonable second or third line option, especially before high-morbidity therapies such as splenectomy or stem cell transplantation.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research
More News: Anemia | Cancer & Oncology | Clinical Trials | Corticosteroid Therapy | Hematology | Laboratory Medicine | Pediatrics | Rituxan | Splenectomy | Stem Cell Therapy | Stem Cells | Thrombocytopenia | Transplants | Velcade